Abstract
KR Murphy, BE Chipps. Ann Allergy Asthma Immunol . 2020;124(3):267–276.e3 To perform a systematic review of published data to evaluate the efficacy and safety of tiotropium, a long-acting muscarinic antagonist (LAMA), as an add-on therapy in children and adolescents with uncontrolled asthma currently on inhaled corticosteroid (ICS) maintenance therapy with or without other controller medications. The systematic review included randomized controlled trials (RCTs) of patients aged 1 to 17 years treated with once daily tiotropium (5µg, 2.5µg, or 1.25 µg administered via slow/soft mist inhaler Respimat) as add on therapy to ICS for 12 or …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
